OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
rights
Q BioMed Inc. finalizes license agreement with OMRF, RGCB
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.